Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated September 19, 2024 (before its estimated September 26, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Primary completion date: Oct 30, 2024 to Sep 26, 2024
    • Study completion date: Dec 30, 2024 to Oct 14, 2024
    v6
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 22
    • Site details revised
    v5
  4. Trial status: Not Yet Recruiting to Recruitingv4 Show 8 more changesShow less
    • Primary endpoint revised
    • Study sites: 0 to 1
    • Primary completion date: Sep 30, 2024 to Oct 30, 2024
    • Study completion date: Mar 30, 2025 to Dec 30, 2024
    • Start date changed from estimate of Sep 25, 2023 to Dec 1, 2023
    • Eligibility criteria expanded, about 110 words
    • Secondary endpoint revised
    • Study description shortened, about 44 words
  5. Secondary endpoints: details revised at 1 of 1 entryv3
  6. Primary endpoint revised
    • Eligibility criteria shortened, about 54 words
    • Secondary endpoint revised
    • Study title shortened, about 6 words
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Trial Details
NCT Number NCT05972278
Lead Sponsor NewAmsterdam Pharma
Collaborators: University of Pennsylvania
Conditions
(from sponsor)		 Lipid Metabolism
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov